The long-term safety and tolerability of ALN-AT3SC evaluated by the proportion of patients experiencing adverse events (AEs), serious adverse events (SAEs), and AEs leading to study drug discontinuation

Change From Baseline in the Number of Bleeding Events

Change From Baseline in the Amount of Factor VIII (FVIII) or Factor IX (FIX) Administered for the Treatment of Bleeding Episodes (FVIII) or factor IX (FIX) and ALN-AT3SC for treatment of bleeding episodes